- Home
- ACIU vs KGEI Comparison
ACIU vs KGEI Comparison
Compare ACIU & KGEI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACIU
- KGEI
- Stock Information
- Founded
- ACIU 2003
- KGEI 2008
- Country
- ACIU Switzerland
- KGEI United States
- Employees
- ACIU N/A
- KGEI N/A
- Industry
- ACIU Biotechnology: Pharmaceutical Preparations
- KGEI
- Sector
- ACIU Health Care
- KGEI
- Exchange
- ACIU Nasdaq
- KGEI Nasdaq
- Market Cap
- ACIU 270.1M
- KGEI 269.7M
- IPO Year
- ACIU 2016
- KGEI N/A
- Fundamental
- Price
- ACIU $2.65
- KGEI $8.32
- Analyst Decision
- ACIU Strong Buy
- KGEI Strong Buy
- Analyst Count
- ACIU 2
- KGEI 1
- Target Price
- ACIU $12.00
- KGEI $11.00
- AVG Volume (30 Days)
- ACIU 203.0K
- KGEI 149.5K
- Earning Date
- ACIU 03-13-2025
- KGEI 11-12-2024
- Dividend Yield
- ACIU N/A
- KGEI N/A
- EPS Growth
- ACIU N/A
- KGEI 2.07
- EPS
- ACIU N/A
- KGEI 0.48
- Revenue
- ACIU $48,505,404.00
- KGEI $54,654,000.00
- Revenue This Year
- ACIU $86.78
- KGEI $15.83
- Revenue Next Year
- ACIU $118.22
- KGEI $26.54
- P/E Ratio
- ACIU N/A
- KGEI $17.06
- Revenue Growth
- ACIU 4097200.00
- KGEI 16.56
- 52 Week Low
- ACIU $2.25
- KGEI $2.85
- 52 Week High
- ACIU $4.98
- KGEI $9.89
- Technical
- Relative Strength Index (RSI)
- ACIU 47.51
- KGEI 58.87
- Support Level
- ACIU $2.39
- KGEI $8.22
- Resistance Level
- ACIU $2.74
- KGEI $9.89
- Average True Range (ATR)
- ACIU 0.14
- KGEI 0.66
- MACD
- ACIU 0.01
- KGEI -0.01
- Stochastic Oscillator
- ACIU 56.52
- KGEI 45.67
About ACIU AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses most of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.
About KGEI Kolibri Global Energy Inc. Common stock
Kolibri Global Energy Inc is a North American energy company focused on finding and exploiting energy projects in oil, gas, and clean and sustainable energy. It is focused on the acquisition, exploration, and production of oil and gas reserves. The company owns and operates shale oil and gas properties in the United States. Its segments include the United States, Canada and Others. The company derives a majority of its revenue from the United States.